STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radiation boost may supercharge immunotherapy for tough liver cancers
Disease control Recruiting nowThis study is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs alone versus immunotherapy plus a precise, high-dose form of radiation called SBRT. The goal is to see if adding radiation helps patients live lon…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 26, 2026 04:27 UTC
-
New drug combo targets tough liver cancer gene mutation
Disease control Recruiting nowThis study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to see if the combination is safe and works better than cabozantinib alone. About 92 adults with liver cancer tha…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:26 UTC
-
Can radiation kickstart the immune system against stubborn cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are getting worse despite immunotherapy. It tests whether giving focused radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiation wh…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
New hope for rare liver cancer: Triple-Drug attack shows promise
Disease control Recruiting nowThis study tests a combination of three drugs—nivolumab (an immunotherapy), fluorouracil (chemotherapy), and interferon alpha-2b (an immune booster)—in people with a rare type of liver cancer called fibrolamellar carcinoma that cannot be surgically removed. The goal is to see if …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
Could a painkiller boost immunotherapy in liver cancer?
Disease control Recruiting nowThis study tests whether adding celecoxib (a painkiller) to standard immunotherapy drugs (durvalumab and tremelimumab) can help control advanced liver cancer that has spread. About 39 adults with advanced or metastatic hepatocellular carcinoma will receive the combination. The go…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New hope for liver cancer: first human trial of AU409 begins
Disease control Recruiting nowThis early-stage trial tests a new drug called AU409 in about 36 adults with advanced liver cancer or other cancers that have spread to the liver. The main goals are to find the safest dose and see if the drug can shrink tumors or stop them from growing. Participants must have tr…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
Electric field therapy worn like a vest shows promise against tough cancers
Disease control Recruiting nowThis early-phase study tests a wearable device that creates low-intensity electric fields to disrupt cancer cell growth, combined with standard drugs (cabozantinib or nab-paclitaxel plus atezolizumab). About 43 adults with advanced solid tumors in the abdomen or chest that have s…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New hope for liver cancer: combo therapy tested after first treatment fails
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (atezolizumab) to a standard targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed and has already been treated with …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New combo therapy for unresectable liver cancer shows promise in early trial
Disease control Recruiting nowThis study is for people with advanced liver cancer that cannot be removed by surgery. It tests a treatment that uses the patient's own immune cells, trained in a lab to attack the tumor, combined with immunotherapy drugs and a pneumonia vaccine, all given after high-dose radiati…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo after radiation shows promise for advanced liver cancer
Disease control Recruiting nowThis study tests whether adding immunotherapy drugs (durvalumab with or without tremelimumab) after standard radiation therapy can help control advanced liver cancer that has spread. About 21 adults whose cancer has worsened despite prior treatment will receive radiation followed…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mary Feng, MD • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Morning or afternoon? new study tests best time for cancer immunotherapy
Symptom relief Recruiting nowThis study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 26, 2026 03:56 UTC
-
Scientists use live camera to peek inside tumors during surgery
Knowledge-focused Recruiting nowThis study uses a special microscope called intravital microscopy (IVM) to watch blood vessels inside solid tumors in real time during surgery. Researchers want to see how these vessels work, which could help decide if a patient's tumor is likely to respond to certain treatments.…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC